- ►annals.org [PDF] S Vadhan-Raj, CF Verschraegen, C Bueso- … - Annals of internal medicine, 2000 - Am Coll Physicians Saroj Vadhan-Raj, MD; Claire F. Verschraegen, MD; Carlos Bueso-Ramos, MD; Hal E.
Broxmeyer, PhD; Andrzej P. Kudelka, MD; Ralph S. Freedman, MD, PhD; Creighton L.
Edwards, MD; David Gershenson, MD; Dennie Jones, MD; Mark Ashby, PhD; and ... Cited by 92 - Related articles - BL Direct - All 4 versions
P Count - Ann Intern Med, 2000 - hem-aids.ru Saroj Vadhan-Raj, MD; Claire F. Verschraegen, MD; Carlos Bueso-Ramos, MD; Hal E.
Broxmeyer, PhD; Andrzej P. Kudelka, MD; Ralph S. Freedman, MD, PhD; Creighton L.
Edwards, MD; David Gershenson, MD; Dennie Jones, MD; Mark Ashby, PhD; and ... Related articles - View as HTML
- ►jcojournal.org RL Basser, C Underhill, I Davis, MD Green, J … - Journal of Clinical Oncology, 2000 - jcojournal.org PATIENTS AND METHODS: In this open-label study, 68 patients with advanced cancer
were randomized to receive PEG-rHuMGDF subcutaneously at different doses and
durations before administration of carboplatin 600 mg/m 2 , ... Cited by 30 - Related articles - BL Direct - All 7 versions
- ►hematologylibrary.org CA Schiffer, K Miller, RA Larson, PC Amrein, … - Blood, 2000 - bloodjournal.hematologylibrary.org Lineage-specific preparations of thrombopoietin have been known to produce
marked increases in the megakaryocyte mass and the platelet count after
subcutaneous dosing. 1 , 2 After promising results in preclinical murine 3 ... Cited by 59 - Related articles - BL Direct - All 3 versions
- ►bloodjournal.org E Archimbaud, OG Ottmann, JAL Yin, K … - Blood, 1999 - Am Soc Hematology To determine the safety, biologic, and clinical benefits of pegylated
recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF;
Amgen, Thousand Oaks, CA) after myelosuppressive chemotherapy in acute ... Cited by 67 - Related articles - BL Direct - All 5 versions
- ►annals.org S Vadhan-Raj, LJ Murray, C Bueso-Ramos, S … - Annals of internal medicine, 1997 - Am Coll Physicians Background: Thrombocytopenia is frequently encountered in patients with cancer.
It is associated with an increased risk for clinically important bleeding
episodes, which increases the demand for platelet transfusion. Cited by 157 - Related articles - BL Direct - All 6 versions
- ►bloodjournal.org DJ Kuter, LT Goodnough, J Romo, J DiPersio, … - Blood, 2001 - Am Soc Hematology Platelet transfusions are essential to prevent morbidity and mortality in
patients who are severely thrombocytopenic. Platelets for transfusion are
currently obtained either by fractionation of whole blood or by platelet ... Cited by 43 - Related articles - BL Direct - All 4 versions
- ►bloodjournal.org J Li, C Yang, Y Xia, A Bertino, J Glaspy, M … - Blood, 2001 - Am Soc Hematology In these clinical studies, both recombinant TPOs were safe and not associated
with thrombosis. However, PEG-rHuMGDF was paradoxically associated with the
development of persistent thrombocytopenia (platelet count 100 × 10 9 /L) ... Cited by 222 - Related articles - BL Direct - All 4 versions
- ►cjp.com [PDF] RA Nash, R Kurzrock, J DiPersio, J Vose, C … - Biology of Blood and Marrow Transplantation, 2000 - Elsevier Delayed platelet recovery is a significant complication after both autologous
and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter,
phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) ... Cited by 38 - Related articles - BL Direct - All 7 versions
B Bolwell, J Vredenburgh, B Overmoyer, C … - Bone marrow transplantation, 2000 - ncbi.nlm.nih.gov Forty-seven patients with stage II, III, or IV breast cancer undergoing
autologous peripheral blood progenitor cell (PBPC) transplantation were
randomized to placebo (n = 13) or to one of five sequential dose cohorts of ... Cited by 24 - Related articles - BL Direct - All 2 versions
